AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00894374
Drug: Artesunate (Test)
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablet, single dose, 1 x 100 mg
Trial: NCT00894374
Drug: Artesunate (Comparator)
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablet, single dose, 2 x 50 mg
Trial: NCT00504582
Drug: Fibrin Sealant
RxNorm normalized name: FIBRIN SEALANT
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisseel applied externally to the dissected axillary area.
Trial: NCT03932201
Drug: Damoctocog alfa pegol (Jivi, Bay94-9027)
RxNorm normalized name: damoctocog alfa pegol
DrugBank: Damoctocog alfa pegol (DB14700)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
Trial: NCT00817219
Drug: Calcipotriene plus betamethasone dipropionate ointment
RxNorm normalized name: betamethasone dipropionate / calcipotriene Topical Cream
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily application for 4 weeks
Trial: NCT04048811
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The induction dose is 2.0mg/mg. The initial maintenance dose of the first 2 subject is 5 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 2 subjects, so as to explore the optimal initial maintenance dose. The adjustment range of the initial maintenance dose is 5 (± 2.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 2.5 mg/kg/h, and the maximum should not be more than 7.5 mg/kg/h.
Trial: NCT04048811
Drug: Propofol HSK3486
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The induction dose of Propofol is 2.0mg/mgThe initial maintenance dose of HSK3486 is fixed at 1 mg/kg/h, without adjustment.
Trial: NCT02927067
Drug: Maribavir
RxNorm normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive 400 mg of maribavir BID orally.
Trial: NCT02927067
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive valganciclovir tablets orally.
Trial: NCT01908738
Drug: paracervical block with 1%lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.~Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes
Trial: NCT01908738
Drug: 10%lidocaine spray
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03072771
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: -Blinatumomab is a bispecific T cell engaging antibody
Trial: NCT03072771
Drug: Carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: -Carmustine is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of carmustine.
Trial: NCT03072771
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: -Etoposide is a semi-synthetic podophyllotoxin derivative. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of etoposide.
Trial: NCT03072771
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: -Cytarabine, commonly known as Ara-C, is a synthetic nucleoside. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of cytarabine.
Trial: NCT03072771
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: -Melphalan is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of melphalan.
Trial: NCT01445054
Drug: 111Indium CHX-A
RxNorm normalized name: 111Indium pentetreotide
DrugBank: Indium (DB11659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 111Indium CHX-A will be administered intravenously over a 10-15 minute period using an intravenous catheter
Trial: NCT01520831
Drug: biphasic insulin aspart 30
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
Trial: NCT01520831
Drug: biphasic insulin aspart 50
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
Trial: NCT01520831
Drug: biphasic insulin aspart 70
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
Trial: NCT01520831
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
Trial: NCT00944385
Drug: ulinastatin
RxNorm normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer 30000U/ulinastatin. Comparison of different dosages of drug.
Trial: NCT00000203
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04074473
Drug: propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)
Trial: NCT02044276
Drug: lipegfilgrastim
RxNorm normalized name: Lipegfilgrastim
DrugBank: Lipegfilgrastim (DB13200)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 6 mg
Trial: NCT02044276
Drug: pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6 mg
Trial: NCT00812305
Drug: SKY0402 300mg in hepatically impaired patients
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in hepatically impaired patients
Trial: NCT01540682
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: \~ 1 week prior to the initiation of radiation therapy and continuing for a grand total of 12 weeks.
Trial: NCT02684318
Drug: PM01183 + olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02278471
Drug: Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)
RxNorm normalized name: POLYPILUS FRONDOSUS WHOLE
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01575288
Drug: High-dose trehalose
RxNorm normalized name: Trehalose
DrugBank: Trehalose (DB12310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100g 1/day
Trial: NCT00083096
Drug: lonafarnib
RxNorm normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00083096
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03468543
Drug: Memantine Hydrochloride MR Prototype Capsule Formulation A
RxNorm normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Trial: NCT01418352
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole tablets once weekly for 8 weeks.
Trial: NCT01637675
Drug: 20 mg sildenafil citrate by mouth
RxNorm normalized name: sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
Trial: NCT01637675
Drug: sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection will also be permitted if necessary) 250ml iv drip once a day for 8 weeks,as well as 20mg sildenafil citrate tablets by mouth three times a day for the same duration of treatment
Trial: NCT00407459
Drug: Bevacizumab, Pemetrexed, Carboplatin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Bevacizumab: 15 mg/kg intravenous infusion over 30 to 90 minutes, following chemotherapy, on Day 1 every 3 weeks~* Pemetrexed: 500 mg/m2 intravenous infusion over 10 minutes on Day 1 every 3 weeks~* Carboplatin: AUC 5 intravenous infusion over 1 hour on Day 1 every 3 weeks
Trial: NCT06568133
Drug: UIC201603 and co-administration of UIC201603 and UIC201604
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * UIC201603 2 Caps/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 days
Trial: NCT06568133
Drug: UIC201604 and co-administration of UIC201603 and UIC201604
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * UIC201604 1 Tabs/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 daysadministration of UIC201603 and UIC201604
Trial: NCT03468543
Drug: Memantine Hydrochloride MR Prototype Capsule Formulation B
RxNorm normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Trial: NCT00406432
Drug: Paroxetine Controlled Release Tablet
RxNorm normalized name: paroxetine Extended Release Oral Tablet
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible subjects will receive paroxetine controlled release tablet with dose of 25 milligrams.
Trial: NCT03468543
Drug: Memantine Hydrochloride MR Prototype Capsule Formulation C
RxNorm normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Trial: NCT03468543
Drug: Memantine Hydrochloride MR Prototype Capsule Formulation D
RxNorm normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Trial: NCT03468543
Drug: Memantine Hydrochloride MR Prototype Capsule Formulation E
RxNorm normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Trial: NCT04514770
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rupture of membrane early and late
Trial: NCT03236493
Drug: PF-06700841
RxNorm normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06700841 will be administered as tablet
Trial: NCT00947245
Drug: BMS-791325
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 300 mg, Single Dose, One day
Trial: NCT00947245
Drug: BMS-791325
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 900 mg, Single Dose, One day
Trial: NCT00947245
Drug: BMS-791325
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, ≤1200 mg, Single Dose, One day
Trial: NCT00947245
Drug: BMS-791325
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 300 mg, Every 12 hours, 14 days
Trial: NCT00947245
Drug: BMS-791325
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 900 mg, once daily 14 days
Trial: NCT00947245
Drug: BMS-791325
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, ≤1200 mg, Every 12 hours or once daily, 14 days
Trial: NCT03603431
Drug: MRG-110
RxNorm normalized name: MRG-003
DrugBank: MRG-003 (DB17407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses of MRG-110
Trial: NCT03603431
Drug: MRG-110
RxNorm normalized name: MRG-003
DrugBank: MRG-003 (DB17407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses of MRG-110
Trial: NCT00765466
Drug: AVR118
RxNorm normalized name: AVR118
DrugBank: AVR118 (DB04979)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily doses of 4.0 mL AVR118 subcutaneously
Trial: NCT00293826
Drug: AMG 108
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg via SC (subcutaneous) injection every 4 weeks
Trial: NCT00293826
Drug: AMG 108
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg via SC (subcutaneous) injection every 4 weeks
Trial: NCT00293826
Drug: AMG 108
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125mg via SC (subcutaneous) injection every 4 weeks
Trial: NCT04014101
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
Trial: NCT00437970
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg of Pioglitazone taken orally twice a day
Trial: NCT00437970
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg of Metformin taken orally twice a day
Trial: NCT04008043
Drug: Vicodin
RxNorm normalized name: Vicodin
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to taking one tablet of vicodin for pain every 4-6 hours up to 8 tablets, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
Trial: NCT04008043
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In addition to taking one tablet of dexamethasone for pain beginning the day before surgery and on the day of surgery, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
Trial: NCT02515812
Drug: I-123-MIBG
RxNorm normalized name: IOBENGUANE SULFATE I-123 25 mCi INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [i 123 MIBG meta iodobenzylguanidine]
DrugBank: Guanidine (DB00536)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04014101
Drug: apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib is a selective VEGFR2 inhibitor.
Trial: NCT00921804
Drug: AZD 8529
RxNorm normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Azdone]
DrugBank: AZD8529 (DB16073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg oral daily capsule administered as a single dose in the morning for 28 days
Trial: NCT00921804
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days
Trial: NCT00921804
Drug: Placebo to match AZD8529
DrugBank: AZD8529 (DB16073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period
Trial: NCT00921804
Drug: Placebo to match risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period
Trial: NCT03798522
Drug: Nalbuphine
RxNorm normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in nalbuphine for analgesia after GA
Trial: NCT02571725
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib starts concomitantly with the first dose of Tremelimumab
Trial: NCT02571725
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 to 6 patients will be treated at 10 mg/kg depending on RLT observed in the first 3 patients. If 0 out of 3 or 1 out of 6 patients experienced a RLT at 10 mg/kg, then this dose will be considered at the recommended phase 2 dose (RP2D). If 2 out of 6 patients experience RLT at this dose within 56 days, then dose reductions as detailed in the Arm description will be carried out.
Trial: NCT01255722
Drug: iobitridol
RxNorm normalized name: iobitridol
DrugBank: Iobitridol (DB12407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single IV injection
Trial: NCT01255722
Drug: iopromide
RxNorm normalized name: Iopromide
DrugBank: Iopromide (DB09156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single IV injection
Trial: NCT01255722
Drug: iomeprol
RxNorm normalized name: IOMEPROL
DrugBank: Iomeprol (DB11705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV injection
Trial: NCT03113825
Drug: AVB-620
RxNorm normalized name: AVB-101
DrugBank: AVB-101 (DB18416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVB-620 will be administered IV before the surgical procedure.
Trial: NCT02519387
Drug: Buprenorphine Transdermal Patch
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02392871
Drug: Dabrafenib and trametinib (combination)
RxNorm normalized name: Dabrafenib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients should be taking dabrafenib and trametinib for at least 2 weeks prior to enrolment into the study.
Trial: NCT06190691
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01825876
Drug: Evacetrapib
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT01186224
Drug: Plerixafor and G-CSF
RxNorm normalized name: G-CSF
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: G-CSF will be given daily from day 1, which will usually be timed to fall toward the end of the working week. Plerixafor will commence on day 4 at as near to 10 PM as practicable, and also on day 5 and subsequent days (maximum of 4 total days) at a similar time of day if insufficient CD34+ cells have been collected. Stem cell harvesting will be carried out on day 5 and if necessary on days 6, 7 and 8, until the target yield of 4 x 106 CD34+ cells /kg recipient weight have been achieved.~The daily dose of G-CSF is 300 ug for patients up to and including 60kg in weight; 480 ug for patients over 60 kg but under 96 kg, and 600 ug for patients weighing 96 kg or more. This equates to a dose of at least 5 ug/kg (maximum 8 mg/kg) for all patients up to 120 kg. The daily dose of plerixafor is 240 ug/kg if the creatinine clearance is equal to or greater than 50mls/minute; if less than this then the dose is 160 ug/kg daily.
Trial: NCT01825876
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT00971685
Drug: Lenalidomide and dexamethasone
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
Trial: NCT00611039
Drug: Darunavir 900mg + ritonavir 100 mg once a day
RxNorm normalized name: ritonavir 100 MG
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darunavir 900mg + ritonavir 100 mg once a day
Trial: NCT00611039
Drug: Darunavir 600mg + ritonavir 100mg twice day
RxNorm normalized name: darunavir 600 MG
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darunavir 600mg + ritonavir 100mg twice day